User profiles for A. L. Benedet
Andréa L. BenedetPostdoctoral Researcher at University of Gothenburg Verified email at gu.se Cited by 6276 |
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Staging of Alzheimer's disease: past, present, and future perspectives
For many years Alzheimer's disease (AD) was associated with the dementia stage of the
disease, the tail end of a pathophysiological process that lasts approximately two decades. …
disease, the tail end of a pathophysiological process that lasts approximately two decades. …
[HTML][HTML] Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging
Alzheimer’s disease (AD) has been reconceptualized as a dynamic pathophysiological
process, where the accumulation of amyloid-beta (Aβ) is thought to trigger a cascade of …
process, where the accumulation of amyloid-beta (Aβ) is thought to trigger a cascade of …
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective …
…, NJ Ashton, S Janelidze, AL Benedet… - The Lancet …, 2020 - thelancet.com
Background CSF and PET biomarkers of amyloid β and tau accurately detect Alzheimer's
disease pathology, but the invasiveness, high cost, and poor availability of these detection …
disease pathology, but the invasiveness, high cost, and poor availability of these detection …
Microglial activation and tau propagate jointly across Braak stages
Compelling experimental evidence suggests that microglial activation is involved in the spread
of tau tangles over the neocortex in Alzheimer’s disease (AD). We tested the hypothesis …
of tau tangles over the neocortex in Alzheimer’s disease (AD). We tested the hypothesis …
[HTML][HTML] Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease
…, P Ortiz-Romero, L Montoliu-Gaya, AL Benedet… - Nature medicine, 2022 - nature.com
Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer’s
disease are needed to facilitate the initial screening process of participants in disease-…
disease are needed to facilitate the initial screening process of participants in disease-…
[HTML][HTML] Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology
The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or
plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology. Tau …
plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology. Tau …
Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum
AL Benedet, M Milà-Alomà, A Vrillon, NJ Ashton… - JAMA …, 2021 - jamanetwork.com
Importance Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease (AD). …
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease (AD). …
[HTML][HTML] Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease
An unresolved question for the understanding of Alzheimer’s disease (AD) pathophysiology
is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) …
is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) …
[HTML][HTML] A multicentre validation study of the diagnostic value of plasma neurofilament light
…, EL van der Ende, TK Karikari, AL Benedet… - Nature …, 2021 - nature.com
Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for
neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a …
neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a …